Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Watchful Waiting

abstract

  • Active surveillance is feasible in patients with low risk prostate cancer and most patients show little evidence of progression within 5 years. There is no clear justification for treating patients in whom prostate specific antigen increases above 10 ng/ml in the absence of other indications of tumor progression. Patients considering active surveillance should undergo confirmatory biopsy to better assess the risk of progression.

publication date

  • February 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3417207

Digital Object Identifier (DOI)

  • 10.1016/j.juro.2010.09.095

PubMed ID

  • 21167529

Additional Document Info

start page

  • 477

end page

  • 82

volume

  • 185

number

  • 2